Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,046 public trials 569 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Completed

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

NCT01239797

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Northwest Alabama Cancer Center, Pc Muscle Shoals, Alabama, United States
  • Acrc/Arizona Clinical Research Center, Inc. Tucson, Arizona, United States
  • Local Institution Berkeley, California, United States
  • Local Institution Burbank, California, United States
View all 216 locations
View Trial Details
Completed

Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment

NCT02977494

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Charité Universitätsmedizin BerlinCampus Benjamin Franklin Berlin, Germany
  • Vivantes Klinikum Neukölln Berlin, Germany
  • Klinikum Chemnitz GmbH Chemnitz, Germany
  • Katholische Karl-Leisner Klinikum Goch Goch, Germany
View Trial Details
Completed

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

NCT03029234

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Beijing Chao Yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Sun Yat-Sen University Cancer Center Guangzhou, Guangdong, China
View all 17 locations
View Trial Details
Completed

Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma

NCT02197221

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Clinique Universitaire Saint Luc Brussels, Belgium
  • Grand Hôpital de Charleroi - Site Notre-Dame Charleroi, Belgium
  • Chu Liege Liège, Belgium
  • CHU Dinant-Godinne UCL Namur Yvoir, Belgium
View all 46 locations
View Trial Details
Completed

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

NCT02677324

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Stanford University Palo Alto, California, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Weill Cornell Medical College New York, United States
View Trial Details
Completed

Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance

NCT01463670

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Stamford Hospital Stamford, Connecticut, United States
  • Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States
  • Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • SUNY Downstate Medical Center Brooklyn, New York, United States
View Trial Details

Related conditions